Dietrich A. Stephan, PhD
Dr. Stephan is an industry veteran having had a career in academia and in industry. Dr. Stephan served as Deputy Director for Discovery Research and Chair of the Neurogenomics Division at TGen and served as Professor and Chairman of the Department of Human Genetics at the University of Pittsburgh/UPMC. He has had academic affiliations with Harvard Medical School, Johns Hopkins University and Children’s National Medical Center.
Dr. Stephan has identified the molecular basis of dozens of rare and common diseases. Dr. Stephan has founded or co-founded 14 biotechnology companies to chaperone novel innovations to market with a focus on molecular diagnostics and first-in-class therapeutics.
Dr. Stephan was co-founder of Navigenics, Inc. (a pioneer in direct-to consumer genomic testing), was founding Chairman of the Board of Pendulum, Inc. (microbiome modulating therapies), and was an early advisor to Guardant Health, Inc. (liquid biopsy). He is also founding Chairman of the Board Peptilogics, Inc. (deep machine learning to develop peptide therapies), was part of the team that developed Genia Technology, Inc.’s single molecule electrical detection DNA sequencing platform acquired by Roche, and others.
Dr. Stephan received his BS from Carnegie Mellon University, PhD from the University of Pittsburgh and did his fellowship at NHGRI/NIH.
View a list of Dr. Stephan’s publications here.
Dr. Stephan’s mailing address is:
NeuBase Therapeutics, Inc.
Chairman and CEO
350 Technology Drive
Pittsburgh, PA 15219
Contact Dr. Stephan via his executive assistant:
Executive Assistant: Jessica Balogh